Motley Fool Australia
  •  

    Notifications

    Scott

    Wondering where you should invest $1,000 right now?

    Scott Phillips just released his 5 best stocks to buy right now and you could grab the names of these stocks instantly!

    Learn More
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Starpharma Holdings Ltd (ASX: SPL)
    3. /

Starpharma Holdings Ltd (ASX: SPL) Share Price and News

Price

$0.097

Movement

0.003 (+3.19%)

As at 23 Apr - Closed (20 mins delayed)

52 Week Range

$0.086 - $0.14

 
1 Year Return

-22.4%

Starpharma Holdings Ltd Chart and Price Data

2025
2025
2025
2025
$0.075
$0.10
$0.125
$0.075
$0.10
$0.125
$0.075
$0.10
$0.125
$0.075
$0.10
$0.125

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $39.31 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 418.22 million
Earnings per share -0.031
Dividend per share N/A
Year To Date Return -12.73%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-12.73%

Shares Outstanding

418.22 million

Earnings per share

-0.031

Share Price

$0.097

Day Change

0.003 (+3.19%)

52 Week Range

$0.086 - $0.14

Yesterday's Close

$0.094

Today's Open

$0.095

Days Range

$0.095 - $0.097

Volume

39,272

Avg. Volume (1 month)

234,829

Turnover

$3,770

As at 23 Apr - Closed

Starpharma Holdings Ltd (ASX: SPL)
Latest News

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

2 ASX healthcare shares outperforming peers on positive company news

| Bronwyn Allen

Mesoblast has announced the resolution of a class action law suit against it today.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Cheap Shares

5 potentially cheap ASX shares being bought by insiders

| Zach Bristow

Insiders see value in these companies.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

3 ASX healthcare shares up 10% to 22% on news

| James Mickleboro

These healthcare shares are catching the eye on Wednesday. But why?

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Delta Lithium, Liontown, Pact, and Starpharma shares are storming higher

| James Mickleboro

These ASX shares are rising despite the market weakness.

Read more »

A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
Healthcare Shares

Here's why the Starpharma share price just exploded 50%!

| James Mickleboro

This biotech is catching the eye of investors on Wednesday. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Earnings Results

4 ASX healthcare shares charging higher on positive earnings updates

| Bronwyn Allen

These ASX healthcare shares are recording strong share price gains today.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why IGO, Patriot Battery Metals, Silver Lake, and Starpharma shares are sinking today

| James Mickleboro

These ASX shares are starting the week in the red.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX All Ords share sinking 34% on Monday?

| James Mickleboro

Investors have been selling off this healthcare share due to some bad news.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

| James Mickleboro

These ASX shares are having a tough time on Tuesday.

Read more »

a woman holds her hands up in delight as she sits in front of her lap
Share Gainers

Why AGL, Retail Food Group, Starpharma, and TPG shares are rising today

| James Mickleboro

These ASX shares have avoided the market selloff...

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Bendigo Bank, Block, Megaport, and Starpharma shares are rising today

| James Mickleboro

These ASX shares are on form on Tuesday...

Read more »

a woman holds a cup to her ear and leans in with a wide mouthed expression on her face as though she is listening to interesting and perhaps surprising information.
52-Week Lows

5 ASX shares trading near 52-week lows that insiders have been buying

| Brooke Cooper

Insiders appear to believe these shares are trading at attractive prices.

Read more »

Frequently Asked Questions

SPL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
4th Apr 2025 2025-04-04T10:05:39 Notification of cessation of securities - SPLYesNo10:05am413k
4th Apr 2025 2025-04-04T10:02:29 Application for quotation of securities - SPLYesNo10:02am616k
17th Mar 2025 2025-03-17T16:12:46 Becoming a substantial holderYesNo4:12pm4150k
26th Feb 2025 2025-02-26T09:44:19 Half Yearly Report and AccountsYesNo9:44am212.5M
29th Jan 2025 2025-01-29T10:16:51 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo10:16am7278k
16th Jan 2025 2025-01-16T14:58:06 DEP Presentation at Targeted Radio Therapies ConferenceYesNo2:58pm282.5M
19th Dec 2024 2024-12-19T09:41:53 SPL receives positive FDA feedback on DEP SN38 for PROCYesNo9:41am3171k
12th Dec 2024 2024-12-12T09:40:16 Change of Director's Interest Notice - Ms Cheryl MaleyYesNo9:40am2298k
12th Dec 2024 2024-12-12T09:26:16 Notification regarding unquoted securities - SPLYesNo9:26am617k
4th Dec 2024 2024-12-04T09:50:48 DEP Presentation at Radiopharmaceuticals SummitYesNo9:50am301.8M

About Starpharma Holdings Ltd

Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.

Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.

Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.

VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.

SPL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Apr 2025 $0.09 $0.00 0.00% 277,385 $0.10 $0.10 $0.09
17 Apr 2025 $0.10 $0.00 0.00% 67,378 $0.10 $0.10 $0.10
16 Apr 2025 $0.10 $0.00 0.00% 202,222 $0.10 $0.10 $0.10
15 Apr 2025 $0.10 $0.00 0.00% 311,093 $0.10 $0.10 $0.10
14 Apr 2025 $0.10 $0.00 0.00% 15,014 $0.10 $0.10 $0.10
11 Apr 2025 $0.10 $0.00 0.00% 5,014 $0.10 $0.10 $0.10
10 Apr 2025 $0.10 $0.00 0.00% 290,473 $0.10 $0.10 $0.10
09 Apr 2025 $0.10 $0.01 10.99% 3,885 $0.10 $0.10 $0.09
08 Apr 2025 $0.09 $0.00 0.00% 24,735 $0.09 $0.09 $0.09
07 Apr 2025 $0.09 $-0.01 -10.53% 717,243 $0.09 $0.09 $0.09
04 Apr 2025 $0.10 $0.00 0.00% 1,001,516 $0.09 $0.10 $0.09
03 Apr 2025 $0.09 $-0.01 -10.20% 92,895 $0.10 $0.10 $0.09
02 Apr 2025 $0.10 $0.00 0.00% 25,345 $0.09 $0.10 $0.09
01 Apr 2025 $0.10 $0.00 0.00% 152,906 $0.10 $0.10 $0.09
31 Mar 2025 $0.09 $0.00 0.00% 373,240 $0.10 $0.10 $0.09
28 Mar 2025 $0.10 $0.00 0.00% 7,161 $0.10 $0.10 $0.10
27 Mar 2025 $0.10 $0.00 0.00% 81 $0.10 $0.10 $0.10
26 Mar 2025 $0.10 $0.00 0.00% 670,693 $0.10 $0.10 $0.10
25 Mar 2025 $0.10 $0.00 0.00% 347,389 $0.10 $0.10 $0.10

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
11 Dec 2024 Cheryl Maley Issued 5,202,703 $598,310
Issue of securities. 7,401,386 Performance Rights, As per announcement on 12-12-2024
05 Nov 2024 Robert Thomas Buy 300,000 $28,000
On-market trade.
23 Oct 2024 Robert Thomas Buy 200,000 $18,500
On-market trade.
23 Oct 2024 Robert Thomas Buy 300,000 $27,750
On-market trade.
13 Sep 2024 Russell Basser Buy 200,000 $18,600
On-market trade.
02 Sep 2024 David McIntyre Buy 405,886 $3,879
On-market trade. As per announcement on 02-09-2024
02 Sep 2024 Robert Thomas Buy 350,000 $3,246
On-market trade.
28 Jun 2024 Jeff Davies Buy 879,687 $79,699
On-market trade.
26 Jun 2024 Robert Thomas Buy 200,000 $17,800
On-market trade.
25 Jun 2024 Lynda Cheng Buy 110,555 $9,950
On-market trade.
20 Jun 2024 Robert Thomas Buy 250,000 $22,679
On-market trade.
30 May 2024 Cheryl Maley Buy 125,000 $14,065
On-market trade.
29 May 2024 Robert Thomas Buy 150,000 $17,750
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Robert Bain Thomas Non-Executive DirectorNon-Executive Chairman Dec 2013
Mr Thomas has background in financial services and capital markets and is a non-executive director of several Australian listed companies. He was previously a Partner of Potter Partners (now UBS), where he was also Head of Research. He is a member of Risk Committee.
Ms Cheryl Ann Maley Chief Executive OfficerManaging Director Jan 2024
Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.
Mr David McIntyre Non-Executive Director Mar 2020
Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. He is the Chair of Risk Committee.
Ms Lynda Cheng Non-Executive Director Aug 2021
Ms Cheng has over 25 years of experience as a finance executive, including substantial international experience and several non-executive directorships, Ms Cheng's experience covers the majority of key areas described in Starpharma's Board skills matrix. In particular, she has expertise in accounting/corporate finance, audit and risk; M&A/capital markets; strategy and risk management; governance; as well as business development. Ms Cheng has had involvement in the commercialisation of new innovations during her tenure at South East Water and also while working with disruptive technology companies in Silicon Valley. She is a member of Risk Committee.
Dr Jeff Davies Non-Executive Director Apr 2022
Dr Davies has over 35 years of experience within the biopharmaceutical industry, Dr Davies is an accomplished executive skilled in R&D, product development and commercialisation strategy, business development, manufacturing and clinical and regulatory affairs. Dr Davies has leadership skills and experience in commercialising scientific research for healthcare products.
Dr Russell Basser Non-Executive Director Feb 2023
Dr Basser has over 20 years of executive experience in the biotechnology industry and 10 years as a practicing clinical oncologist, Dr Basser has leadership skills and experience in healthcare/scientific research; pharmaceutical product development; international executive experience and skills in regulation/public policy; commercialisation of innovation; business development; governance; strategy; and risk management.
Mr Justin Cahill Chief Financial OfficerCompany Secretary Apr 2023
-
Justin Cahill Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 81,247,474 19.70%
JP Morgan Nominees Australia PTY Limited 31,174,308 7.56%
Citicorp Nominees Pty Limited 15,203,959 3.69%
BNP Paribas Noms Pty Ltd 14,494,331 3.51%
Bell Potter Nominees Ltd <Bb Nominees A/C> 9,000,000 2.18%
Ingot Capital Investments Pty Ltd 8,705,000 2.11%
T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> 5,060,000 1.23%
BNP Paribas Nominees Pty Ltd <Clearstream> 4,866,370 1.18%
Mr Kingsley Bryan Bartholomew 4,612,025 1.12%
Lavya Pty Ltd <Lavya Family A/C> 4,344,628 1.05%
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 4,267,008 1.03%
HSBC Custody Nominees (Australia) Limited A/C 2 4,141,107 1.00%
Mr Peter Murray Jackson 3,921,959 0.95%
E Equities Pty Ltd 3,700,000 0.90%
All States Finance Pty Limited 3,500,000 0.85%
Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> 3,361,550 0.82%
Ms Jacinth Fairley 3,252,386 0.79%
Charles & Cornelia Goode Foundation Pty Ltd <CCG Foundation A/C> 3,200,000 0.78%
Mr Thomas Argyrou 3,000,000 0.73%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> 2,739,822 0.66%

Profile

since

Note